Open AccessEvidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis
Author(s) -
Diana Prieto Peña,
I. Martínez-Rodríguez,
Belén AtienzaMateo,
Monica Calderón-Goercke,
Ignacio Banzo,
M. Carmen GonzálezVela,
Santos Castañeda,
Javier Llorca,
Miguel A. GonzálezGay,
Ricardo Blanco
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/mjm8fr
Subject(s) - medicine , tocilizumab , giant cell arteritis , interquartile range , nuclear medicine , positron emission tomography , aortitis , radiology , aorta , vasculitis , disease
Clinical improvement following tocilizumab (TCZ) therapy in patients with large-vessel (LVV) giant cell arteritis (GCA) is well established. However, information on TCZ effect on imaging vascular activity is limited. We aimed to determine if clinical improvement correlated with reduction of vascular 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography (PET/CT) scans.